Molecular mechanisms of resistance to tamoxifen therapy in breast cancer.
Clinical data suggest that the use of adjuvant tamoxifen citrate (Nolvadex) for a minimum of 5 years, and possibly indefinitely, will result in maximal antitumor benefit. There is concern that long-term tamoxifen maintenance therapy may result in the induction of drug resistance. This article reviews the potential molecular mechanisms of resistance to tamoxifen and explores the possibility of tamoxifen-stimulated tumor growth.
Morrow
M
M
Department of Surgery, University of Chicago, Ill.
Jordan
V C
VC
D001667:Binding, Competitive; D001943:Breast Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000378:metabolism* / Q000473:pathology; D017024:Chemotherapy, Adjuvant; D004351:Drug Resistance; D004967:Estrogens / Q000097:blood; D005260:Female; D006801:Humans; D007536:Isomerism; D008593:Menopause; D008967:Molecular Biology; D009154:Mutation; D009367:Neoplasm Staging; D011960:Receptors, Estrogen / Q000187:drug effects / Q000235:genetics; D015398:Signal Transduction / Q000187:drug effects / Q000235:genetics; D013629:Tamoxifen / Q000737:chemistry* / Q000378:metabolism* / Q000494:pharmacology / Q000627:therapeutic use; D013997:Time Factors; D014158:Transcription, Genetic / Q000187:drug effects / Q000235:genetics
D004967:Estrogens; D011960:Receptors, Estrogen; D013629:Tamoxifen